Skip to content
Unrated Drug recall · FDA · Published July 28, 2022

Lupin Rifampin Capsules Recall: Impurity Risk in 150mg Dose

Lupin Pharmaceuticals recalls 150mg Rifampin capsules due to impurity detected in manufacturing. This may affect safety for patients using prescription medication. Contact for details.

🇺🇸 FDA recall #D-1343-2022DrugLupin Pharmaceuticals ›
Take action

Contact the company

Recalling firmLupin Pharmaceuticals Inc.Harborplace Tower, 111 S Calvert St Fl 21st · Baltimore, MD 21202-6174
✎ GovInfoNow plain-language explainer

Lupin Pharmaceuticals is recalling 150mg Rifampin capsules because a chemical impurity was found during manufacturing. This could pose a safety risk for patients taking the medication as prescribed. Read more at govinfonow.com/recall/34387-lupin-rifampin-capsules-recall-impurity-risk-in-150mg-dose.

Source Summary by GovInfoNow · govinfonow.com/recall/34387-lupin-rifampin-capsules-recall-impurity-risk-in-150mg-dose · Updated September 23, 2026 · FDA enforcement record: FDA #D-1343-2022

Cite this page

“Lupin Rifampin Capsules Recall: Impurity Risk in 150mg Dose.” GovInfoNow, updated September 23, 2026. https://govinfonow.com/recall/34387-lupin-rifampin-capsules-recall-impurity-risk-in-150mg-dose. Based on FDA recall #D-1343-2022 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1343-2022%22&limit=1).

The FDA announced on July 28, 2022, that Lupin Pharmaceuticals Inc. voluntarily recalled Rifampin Capsules, USP, 150 mg due to CGMP deviations involving out-of-specification results for the MNP impurity. The recall affects 7,872 bottles distributed nationwide.

How to tell if you have it

  • Brand: Lupin Pharmaceuticals
  • Product: Rifampin Capsules, USP, 150 mg
  • Packaging: 30 count HDPE bottles
  • NDC: 68180-658-06
  • Lot #: A200170
  • Expiration date: December 2023

The hazard

The recall was initiated because an out-of-specification result was observed in the 1-Methyl-4-Nitroso Piperazine (MNP) impurity during manufacturing. The FDA classified this as a Class II recall.

Context

GovInfoNow's records show Lupin Pharmaceuticals Inc. has 90 other recalls on record since January 31, 2013. Recent brand recalls include the August 3, 2026 Clobetasol Cream Recall for failed content uniformity and the June 23, 2026 Glucagon Emergency Kit Recall for CGMP deviation risks. Other recent recalls of similar products include the May 14, 2026 Asclemed Duloxetine Capsules Recall, the October 22, 2025 Zydus Clomipramine Capsules Recall, and the March 27, 2026 Appco Pharma Prazosin Capsules Recall.

How to tell if you have this one

Check for Rifampin Capsules, USP, 150 mg, 30 count HDPE bottles with NDC 68180-658-06 and Lot #A200170, expiring December 2023. The product is prescription-only and manufactured by Lupin Pharmaceuticals in Baltimore, MD.

  • Brand
    Lupin Pharmaceuticals
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Product Details

    Verify if your Rifampin capsules match the NDC 68180-658-06 and Lot #A200170 with expiration December 2023.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Product was distributed nationwide.” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 14 months after the firm started it.

1. Firm started the recall: Jul 28, 202212. FDA classified it Class II: Aug 16, 202223. Published in FDA’s Enforcement Report: Aug 24, 202234. FDA terminated the recall: Oct 5, 2023420222023
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Other Lupin Pharmaceuticals recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-1343-2022 (July 28, 2022) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1343-2022 to see it in context.
  • Plain-language summary written by qwen3:4b on September 23, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA